Clinical and Biological Aspects of the MONKEYPOX Disease

Key facts

Sponsor

Institut Pasteur

Principal Investigator

Fabien Taieb, MD

Institut Pasteur

Intervention

Blood sample collection(other)

Enrollment

330 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2026

Study locations (1)

• Centre Médical de l'Institut Pasteur, Paris, France

Collaborators

Centre Médical de l'Institut Pasteur

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Human infection by orthopoxvirus

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07199569
  Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
  Bavarian Nordic
• RECRUITINGPHASE2NCT06839989
  An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
  Institute of Tropical Medicine, Belgium
• ACTIVE NOT RECRUITINGPHASE3NCT06844487
  Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
  Jean-Pierre Van geertruyden
• RECRUITINGNCT06885853
  Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE1NCT06771479
  A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
  Shanghai Institute Of Biological Products
• ACTIVE NOT RECRUITINGPHASE2NCT06549530
  Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
  Bavarian Nordic
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT06366672
  Evaluating the Human Immune Response to the JYNNEOS Vaccine
  Washington University School of Medicine

See all trials for Human infection by orthopoxvirus →